---
$id: https://graph.org.ai/products/commodity/51131716
$type: Product
source: UNSPSC
code: "51131716"
title: "Reteplase"
class: "51131700"
classTitle: "Thrombolytic drugs and platelet aggregation inhibitors"
family: "51130000"
familyTitle: "Hematolic drugs"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Reteplase

**UNSPSC Code**: 51131716
**Class**: [Thrombolytic drugs and platelet aggregation inhibitors](Thrombolytic drugs and platelet aggregation inhibitors.mdx)
**Family**: [Hematolic drugs](../Hematolic drugs.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes a plasminogen activator with the molecular formula C1736H2653N499O522S22, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DQA630RIE9, more generally known as reteplase. European Medicines Agency schedules reteplase in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10290MIG. The term RETEPLASE is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 8 no. 3 1994, list 34. Most nations schedule reteplase under HS 35079090 and SITC 51691. As of Q4 2014, RETEPLASE remains the US FDA Preferred Term for this commodity. Reteplase bears US NLM identifiers UMLS ID C0106660 and NCI Concept Code C90972. SMILES: NONE.

